一、主要会计数据和财务指标 前十大流通股东累计持有： 5444.3万股，累计占流通股比： 41.66%，较上期变化： -207.49万股。 | 名称 | 持有数量(万股) | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 西北有色金属研究院 | 3360.00 | 25.71 | 不变 | | 张之翔 | 550.66 | 4.21 | 不变 | | 汇添富基金管理股份有限公司-社保基金17022组合 | 310.79 | 2.38 | -27.21 | | 西安航天新能源产业基金投资有限公司 | 228.85 | 1.75 | -138.27 | | 基本养老保险基金一六零三二组合 | 199.67 | 1.53 | 不变 | | 王鹏宝 | 178.01 | 1.36 | -1.60 | | 文永忠 | 168.00 | 1.29 | 不变 | | 中信建投（601066）投资有限公司 | 163.52 | 1.25 | 不变 | | 汇添富基金管理股份有限公司-社保基金四二三组 合 | 151.51 | 1.16 | -40 ...

Group 1 - The core viewpoint of the news is that Baoxiniang (002154.SZ) reported a total of 1.53 billion shares held by 129 institutional investors, accounting for 10.46% of the total share capital as of April 18, 2025 [1] - The top ten institutional investors hold a combined 6.89% of the shares, with a decrease of 5.24 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, eight funds reported a decrease in holdings, with a reduction rate of 2.70% compared to the previous quarter [2] - A total of 116 new public funds were disclosed this period, including major funds like Huaxia CSI 1000 ETF and Huitianfu Consumer Industry Mixed Fund [2] - One foreign fund, Hong Kong Central Clearing Limited, reported a decrease in holdings, with a reduction rate of 2.49% [2]

来源：金融界 公开信息显示，现任基金经理孙浩先生:中国国籍,学历:北京大学金融硕士。从业资格:证券投资基金从 业资格,CFA。2020年7月起任汇添富基金管理股份有限公司数量分析师。2023年8月29日至今任汇添富 中证国企一带一路交易型开放式指数证券投资基金联接基金的基金经理。2023年8月29日至今任中证上 海国企交易型开放式指数证券投资基金联接基金的基金经理。2023年8月29日至2025年03月18日任汇添 富深证300交易型开放式指数证券投资基金联接基金的基金经理。2023年8月29日至今任中证银行交易型 开放式指数证券投资基金联接基金的基金经理。2023年9月28日至今任中证长三角一体化发展主题交易 型开放式指数证券投资基金联接基金的基金经理。2023年11月28日至今任汇添富MSCI中国A50互联互 通交易型开放式指数证券投资基金联接基金的基金经理。2023年11月28日至今任汇添富中证沪港深张江 自主创新50交易型开放式指数证券投资基金的基金经理。2023年12月12日至今任汇添富上证综合交易型 开放式指数证券投资基金的基金经理。2023年12月12日至今任汇添富中证2000交易型开放式指数证 ...

4月17日，汇添富中证全指证券公司ETF联接(LOF)C（501048）下跌0.06%，最新净值1.05元，连续3个 交易日下跌，区间累计跌幅0.51%。 据了解，汇添富中证全指证券公司ETF联接(LOF)C成立于2017年12月，基金规模7.88亿元，成立来累计 收益率4.59%。从持有人结构来看，截至2024年末，汇添富中证全指证券公司ETF联接(LOF)C的基金机 构持有0.25亿份，占总份额的3.72%，个人投资者持有6.41亿份，占总份额的96.28%。 公开信息显示，现任基金经理董瑾女士:国籍:中国,北京大学西方经济学硕士。从业资格:证券投资基金 从业资格。2010年8月至2012年12月任国泰基金管理有限公司产品经理助理,2012年12月至2015年9月任 汇添富基金管理股份有限公司产品经理,2015年9月至2016年10月任万家基金管理有限公司量化投资部基 金经理助理。2016年11月加入汇添富基金管理股份有限公司。2017年12月18日至2019年12月31日任汇添 富沪深300指数型发起式证券投资基金(LOF)的基金经理助理。2017年12月18日至2019年12月31日任汇 添富中证全指 ...

截止2024年12月31日，汇添富中证医药ETF联接A前三持仓占比合计1.09%，分别为：23国债05 （0.77%）、24国债02（0.20%）、24国债09（0.12%）。 来源：金融界 4月17日，汇添富中证医药ETF联接A（007076）下跌0.08%，最新净值0.86元，连续3个交易日下跌，区 间累计跌幅0.63%。 据了解，汇添富中证医药ETF联接A成立于2019年3月，基金规模1.21亿元，成立来累计收益 率-14.39%。从持有人结构来看，截至2024年末，汇添富中证医药ETF联接A的基金机构持有0.02亿份， 占总份额的1.28%，个人投资者持有1.36亿份，占总份额的98.72%。 公开信息显示，现任基金经理过蓓蓓女士:国籍:中国,中国科学技术大学金融工程博士研究生。曾任国泰 基金管理有限公司金融工程部助理分析师、量化投资部基金经理助理。2015年6月加入汇添富基金管理 股份有限公司。2015年8月3日至今任汇添富中证主要消费交易型开放式指数证券投资基金联接基金的基 金经理。2015年8月3日至2023年4月13日任中证金融地产交易型开放式指数证券投资基金的基金经理。 2015年8月3日至 ...

Core Viewpoint - Huatai Chemical Co., Ltd. has experienced a significant decline in stock price, with a cumulative drop of -31.09% over seven consecutive trading days, indicating potential challenges in the company's market performance [1]. Company Overview - Huatai Chemical is a modern, comprehensive chemical enterprise focused on the manufacturing of basic chemicals, fine chemicals, and new chemical materials, serving various downstream industries including chemical manufacturing, biomedicine, metal smelting, agricultural environmental protection, polymer materials, new energy, and wet electronic chemicals [1]. - The company has established long-term cooperative relationships with leading enterprises in the industry [1]. Financial Performance - The fund managed by Huatai, specifically the Huatai CSI 300 Index Enhanced A, has entered the top ten shareholders of Huatai Chemical, indicating a strategic investment move [1]. - The fund has reported a year-to-date return of -6.26%, ranking 1750 out of 3442 in its category, suggesting underperformance compared to peers [1]. Fund Manager Profile - Xu Yizun, the fund manager of Huatai CSI 300 Index Enhanced A, has been with Huatai Fund Management since July 2010 and has extensive experience managing various funds, including the Huatai Growth Multi-Factor Quantitative Strategy Fund and the Huatai CSI Chip Industry Index Enhanced Fund [3][4].

公开信息显示，现任基金经理孙浩先生:中国国籍,学历:北京大学金融硕士。从业资格:证券投资基金从 业资格,CFA。2020年7月起任汇添富基金管理股份有限公司数量分析师。2023年8月29日至今任汇添富 中证国企一带一路交易型开放式指数证券投资基金联接基金的基金经理。2023年8月29日至今任中证上 海国企交易型开放式指数证券投资基金联接基金的基金经理。2023年8月29日至2025年03月18日任汇添 富深证300交易型开放式指数证券投资基金联接基金的基金经理。2023年8月29日至今任中证银行交易型 开放式指数证券投资基金联接基金的基金经理。2023年9月28日至今任中证长三角一体化发展主题交易 型开放式指数证券投资基金联接基金的基金经理。2023年11月28日至今任汇添富MSCI中国A50互联互 通交易型开放式指数证券投资基金联接基金的基金经理。2023年11月28日至今任汇添富中证沪港深张江 自主创新50交易型开放式指数证券投资基金的基金经理。2023年12月12日至今任汇添富上证综合交易型 开放式指数证券投资基金的基金经理。2023年12月12日至今任汇添富中证2000交易型开放式指数证券投 资基金的 ...

Group 1 - Company EnGene Biotech-B (09606.HK) plans to officially list on the Hong Kong Stock Exchange on April 15, having secured a prestigious lineup of cornerstone investors including BioNTech [1] - EnGene Biotech, established in 2019, focuses on developing antibody-drug conjugates (ADCs) aimed at treating cancer and autoimmune diseases, with two core products: DB-1303/BNT323 targeting HER2 for endometrial and breast cancer, and DB-1311/BNT324 targeting B7-H3 for small cell lung cancer, castration-resistant prostate cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma [1] - The company also has five other ADCs in clinical stages and two bispecific ADCs (BsADCs) expected to enter clinical stages between 2025 and 2026, along with several preclinical ADCs [1] Group 2 - The company is offering a total of 15.0716 million shares globally, with 1.5072 million shares available in Hong Kong and 13.5644 million shares for international offering, plus a 15% over-allotment option [2] - The subscription period for the shares is from April 7 to April 10, 2025, with an expected share price range of HKD 94.60 to HKD 103.20, and assuming a price of HKD 98.90, the estimated net proceeds would be approximately HKD 1.3703 billion [2] - Cornerstone investors have committed to subscribe for a total of USD 65 million (approximately HKD 505.4 million) in shares, including major investors such as BioNTech and various healthcare-focused funds [3]

Group 1 - The innovation drug sector is experiencing increased attention from institutional investors, with significant participation from enterprise annuities and pension funds in newly established ETFs [1][2] - The Industrial Bank of China’s ETF has 95.67% of its shares held by institutional investors, with enterprise annuities dominating the top holders [1] - Major state-owned banks' enterprise annuities are among the top holders, with significant shares exceeding 40 million [1][2] Group 2 - The performance of innovation drug ETFs has been strong, with several funds showing over 25% growth year-to-date [3] - Fund managers are optimistic about the innovation drug sector, indicating a structural change in the market and increased allocations to CRO and CDMO sectors [3][4] - The implementation of new drug registration regulations has shortened approval times, leading to a predicted significant performance release in the innovation drug industry by 2025 [4]

Group 1 - Enhua Pharmaceutical (002262.SZ) released its 2024 annual report on March 29, 2025, indicating that as of March 28, 2025, 162 institutional investors disclosed holding A-shares, totaling 438 million shares, which accounts for 43.14% of the total share capital [1] - The top ten institutional investors include Xuzhou Enhua Investment Co., Ltd., Hong Kong Central Clearing Limited, and several funds, with the top ten collectively holding 38.60% of the shares, a decrease of 1.15 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, Morgan Stanley's Yuyao Anhe Mixed A, increased its holdings, while eight funds, including China Europe Medical Health Mixed A and others, reduced their holdings, with a total decrease of 1.16% [2] - A total of 127 new public funds were disclosed this period, including several from Invesco Great Wall and others, while 33 funds were not disclosed this period, including various funds from Huatai-PineBridge [2] - Foreign investment sentiment showed a decrease in holdings from one foreign fund, Hong Kong Central Clearing Limited, with a reduction of 0.36% [2]